Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

THE USE OF CARBONIC ANHYDRASE INHIBITORS IN THE RETREATMENT OF CYSTIC MACULAR LESIONS IN RETINITIS PIGMENTOSA AND X-LINKED RETINOSCHISIS

Thobani, Azzrah OD; Fishman, Gerald A MD

doi: 10.1097/IAE.0b013e3181e587f9
Original Study
Buy

Purpose: The purpose of this study was to determine if carbonic anhydrase inhibitors can restore their efficacy after a period of discontinued use in patients with cystic foveal lesions who demonstrated subsequent worsening in the extent of their foveal cysts after initially exhibiting a favorable response to treatment.

Methods: Retrospective chart review was conducted on all patients with retinitis pigmentosa or X-linked retinoschisis who were either currently on treatment or had been treated with carbonic anhydrase inhibitors for cystic macular lesions. A total of three patients were included in the study.

Results: All three patients exhibited a recurrence of their cystic macular lesions while on treatment with carbonic anhydrase inhibitors. After discontinuing treatment for a period of 1 month to 6 months, all patients showed a favorable response to retreatment as monitored with optical coherence tomography scans.

Conclusion: The present study shows that patients who show signs of recurring macular cysts while still on treatment can have a favorable response when treatment is reinstated after a period of discontinued use of a carbonic anhydrase inhibitor.

The present study shows that patients who show signs of recurring macular cysts while still on treatment can have a favorable response when treatment is reinstated after a period of discontinued use of a carbonic anhydrase inhibitor.

From the *Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois.

Supported in part by The Foundation Fighting Blindness, Owing Mills, MD, and Grant Healthcare Foundation, Chicago, IL (G.A.F.); National Institutes of Health core grant EY01792; and an unrestricted departmental grant from Research to Prevent Blindness.

The authors have no financial or proprietary interest in any of the products or techniques mentioned in this article.

Reprint requests: Dr Gerald A. Fishman, MD, 1855 West Taylor Street, Suite 3.85, Chicago, IL 60612; e-mail gerafish@uic.edu

© The Ophthalmic Communications Society, Inc.